NCT03077672View on ClinicalTrials.gov

Mitochondrial DNA as a Biomarker of Sepsis Severity

CompletedOBSERVATIONAL
Enrollment

1,304

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Sepsis SyndromeSepsisSevere SepsisSeptic ShockInfection
Trial Locations (2)

10065

New York Presbyterian/Weill Cornell Medicine, New York

11215

New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn

All Listed Sponsors
collaborator

New York Presbyterian Hospital

OTHER

collaborator

New York Presbyterian Brooklyn Methodist Hospital

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT03077672 - Mitochondrial DNA as a Biomarker of Sepsis Severity | Biotech Hunter | Biotech Hunter